Myocardial Ischemia Clinical Trial
Official title:
Perioperative Ischemia Reduction Study (PROSE) Pilot
After surgery, patients who have cardiogram changes consistent with a lack of oxygen to the heart muscles, also known as myocardial ischemia, have been found to have 9 times the chance of having an event such as a heart attack during the subsequent 30 days. It is not known if monitoring and treating ischemia will prevent events such as heart attacks. It is not known if such monitoring and treatment can be done on the regular surgical wards. In this pilot study, we hope to demonstrate that such a study is feasible, and the maintenance of blinding is possible. The primary outcomes are to show that such monitoring after surgery is possible in ≥ 95% of patients, to show that response and treatment to such ischemia in ≤ 1 hour is possible in ≥ 90% of patients, and that blinding between the standard and active treatment groups is possible for 50% ± 1 s.d.. With the pilot study data, if successful, we will be applying for peer-reviewed funding for a full study.
Perioperative myocardial ischemia has been studied in the pre-, intra-, and postoperative
periods. The intraoperative incidence is similar to the preoperative period but the
postoperative incidence is doubled that of the preoperative period. These results have two
implications: postoperative myocardial ischemia cannot be predicted by preoperative
ambulatory ECG monitoring since only half of those are seen preoperatively; the
postoperative period is when significant myocardial ischemia occurs.
The role of myocardial ischemia, especially prolonged ischemia, in perioperative myocardial
infarction (PMI) has been recognized by a number of investigators. In the presence of
postoperative myocardial ischemia, the relative risk of a postoperative cardiac event was 16
in one study and the odds ratio for an ischemic cardiac event was 9.2 in another. Using
12-lead continuous monitoring, one study found that all PMI were preceded by myocardial
ischemia.
Ambulatory ECG in the postoperative period has been well reported in the past. Recently,
Landesberg reported the sensitivity and specificity of lead placements to detect myocardial
ischemia in the postoperative period. Lead combinations were compared with continuous
12-lead ECG in 185 consecutive patients. Combining two precordial leads, the sensitivity for
detecting ischemia was 97.4% for V3 + V5; 92.1% for V4 + V5; and for infarction was 100% for
V3 + V5 or V4 + V5.
We believe that the pathogenesis of PMI is multifactorial. Apart from the coronary anatomy
and the vulnerable plaque, stress hormones and catecholamine surges in the perioperative
period are well reported. Stress increases systolic BP, which is a major determinant of LV
wall tension, and hence, myocardial oxygen demand. The oxygen cost of "pressure work" is
greater than "volume work", with the area-under-the-curve for LV pressure closely
correlating with myocardial oxygen demand. Hypercoagulable state has also been implicated in
PMI.
With so many possible pathogenesis, it is our belief therefore that postoperative myocardial
ischemia may be one of the final pathways just before postoperative ischemic cardiac
complications. This is especially so when all PMI were preceded by myocardial ischemia in
one study. With potentially multiple pathogenesis, it is unknown if postoperative myocardial
ischemia is amenable to treatment. It is, however, our belief that postoperative myocardial
ischemia can be aborted using existing treatment modalities. The implication is that the
reduction of postoperative myocardial ischemia may reduce the incidence of postoperative
ischemic cardiac complications, including PMI.
Current standard of care does not include telemetry or real-time ST monitoring on surgical
patients. Traditional telemetry would impede low-risk patients in their postoperative
recovery by limiting them to their beds. In the context of real-time monitoring for ST
changes in low-risk patients, the cost of traditional telemetry with nursing may also be
prohibitive. We propose a novel technological application, transmitting wireless ST segment
monitoring and alarms to a Blackberry. This will alert the research team to verify via "full
disclosure" on the ST monitor and respond directly. SpaceLab, GlobeStar, and Research in
Motion (RIM) have developed the hardware and software respectively. We currently have
written assurances and support from SpaceLab, GlobeStar, and RIM to conduct a pilot study
for this novel application (see attached). We therefore propose a pilot study to determine
the feasibility of wireless ST-segment monitoring and its treatment in post-surgical
patients.
;
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
| Recruiting |
NCT05846893 -
Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease
|
N/A | |
| Completed |
NCT04153006 -
Comparison of Fingerstick Versus Venous Sample for Troponin I.
|
||
| Completed |
NCT01205776 -
EXCEL Clinical Trial
|
N/A | |
| Active, not recruiting |
NCT04555174 -
BIOFLOW-VIII All-comers Orsiro Mission Safety and Performance Registry
|
||
| Recruiting |
NCT04582877 -
Pressure Guidewire System Multi-center, Prospective, Self-Control, Clinical Trial
|
N/A | |
| Recruiting |
NCT04390672 -
Multivessel TALENT
|
N/A | |
| Recruiting |
NCT03265535 -
Validation of a Single Rest-Stress Imaging Protocol for Myocardial Perfusion Imaging
|
||
| Not yet recruiting |
NCT04522583 -
Increased CRP Concentrations in Patients Admitted to the Emergency Department With Troponin Elevation Aids to Rule Out Coronary Ischemia
|
||
| Completed |
NCT02510547 -
Comparison of a CrossBoss First Versus Standard Wire Escalation Strategy for Crossing Coronary Chronic Total Occlusion: the "CrossBoss First" Trial
|
Phase 4 | |
| Terminated |
NCT02407626 -
Optimization of Cardioprotection in Diabetic Patients Undergoing Cardiac Surgery
|
N/A | |
| Completed |
NCT02554006 -
Predischarge Bundle to Minimize Negative Impact on Quality of Life of Nuisance Bleedings
|
N/A | |
| Active, not recruiting |
NCT02189499 -
Feasibility Study of the Amaranth Medical FORTITUDE Bioresorbable Drug-Eluting Coronary Stent
|
Phase 2 | |
| Completed |
NCT02197065 -
Pilot Study of Atorvastatin for Orthopedic Surgery Patients
|
Phase 2 | |
| Completed |
NCT02264717 -
Dan-NICAD - Danish Study of Non-Invasive Diagnostic Testing in Coronary Artery Disease
|
N/A | |
| Recruiting |
NCT01681381 -
Evaluate Safety And Effectiveness Of The Tivoli® DES and The Firebird2® DES For Treatment Coronary Revascularization
|
N/A | |
| Terminated |
NCT01892917 -
BIOFLOW-III Hungary Satellite Registry
|
N/A | |
| Completed |
NCT01679886 -
Comparison of Rubidium PET and SPECT With CZT Crystals for Detection of Myocardial Ischemia in Overweighed Patients and Women
|
N/A | |
| Completed |
NCT01655043 -
Absolute Quantification of Coronary Flow Reserve by Stress Perfusion MRI
|
Phase 2 | |
| Completed |
NCT02707445 -
Genotyping Influences Outcome of Coronary Artery Stenting
|
N/A |